Fachrepositorium Lebenswissenschaften

67 Treffer

Seiten

Suche

Publisso-Menue

Seiten

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

2021 . Blasi, Miriam | Kazdal, Daniel | Thomas, Michael | Christopoulos, Petros | Kriegsmann, Mark | Brandt, Regine | Volckmar, Anna-Lena | Kirchner, Martina | Heußel, Claus Peter | Stenzinger, Albrecht | Kuon, Jonas

Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting

KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials

2021 . Zhu, Hongyuan | Xie, Daipeng | Yu, Yunfang | Yao, Lintong | Xu, Bin | Huang, Luyu | Wu, Shaowei | Li, Fasheng | Zheng, Yating | Liu, Xinyi | Xie, Wenzhuan | Huang, Mengli | Li, Hao | Zheng, Shaopeng | Zhang, Dongkun | Qiao, Guibin | Chan, Lawrence W. C. | Zhou, Haiyu

Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC

2021 . Jagoda, Philippe | Fleckenstein, Jochen | Sonnhoff, Mathias | Schneider, Günther | Ruebe, Christian | Buecker, Arno | Stroeder, Jonas

SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer

2021 . Xu, Rui | Luo, Xin | Ye, Xuan | Li, Huan | Liu, Hongyue | Du, Qiong | Zhai, Qing

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

2021 . Xiong, Qi | Qin, Boyu | Xin, Lingli | Yang, Bo | Song, Qi | Wang, Yu | Zhang, Sujie | Hu, Yi

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients

2021 . Taugner, Julian | Käsmann, Lukas | Eze, Chukwuka | Rühle, Alexander | Tufman, Amanda | Reinmuth, Niels | Duell, Thomas | Belka, Claus | Manapov, Farkhad

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors

2021 . Araujo-Fernandez, I. | Delgado, J. | Moscetti, L. | Sarac, S. B. | Zander, Hilke | Müller-Egert, Susanne | Dunder, K. | Pean, E. | Bergmann, L. | Enzmann, H. | Pignatti, F.

Potential of German claims data to characterize utilization of new cancer drugs: the example of crizotinib

2021 . Schwarz, Sarina | Oppelt, Katja Anita | Heinig, Miriam | Haug, Ulrike

Lorlatinib als vielversprechendes Medikament in der zukünftigen Therapie des fortgeschrittenen ALK-positiven nichtkleinzelligen Bronchialkarzinoms

2021 . Richter, Johanna | Dunst, Jürgen

Seiten